Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Murali Chintagumpala M.D.

Murali Chintagumpala, M.D.


Murali Chintagumpala, M.D.

Murali Chintagumpala, M.D.

Senior Member
The Methodist Hospital Research Institute
Department of Pediatrics 
Section of Hematology/Oncology
Clinical Director
Neuro-oncology Team
Texas Children's Cancer Center

E-mail: mxchinta@txccc.org
Phone: 832-822-4266
Fax: 832-822-1456


M.D.   Madras Medical School, India

Postdoctoral Training

Residency, Columbus Hospital, Chicago, IL
Fellowship, Baylor College of Medicine, Houston, TX

Description of Research

Dr. Chintagumpala is the principal investigator of two multi-institutional studies designed to improve survival in patients with osteosarcoma and the treatment of medulloblastoma. He is a member of the Brain Tumor Committee and study chairman for a new protocol for children with low-grade gliomas. He is also a key investigator in a study to better delineate the risk factors for the development of metastases in children with retinoblastomas, and a gene therapy study at the Texas Children's Cancer Center for the treatment of children with retinoblastomas.

Major Areas of Research

Neuro-oncology, Solid Tumors, Retinoblastoma, Osteosarcoma, Wilms Tumors

Recent Publications

Paulino AC, Mazloom A, Teh BS, South M, Okcu MF, Su J, Butler EB, Chintagumpala M. Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2010 Sep 15.

Paulino AC, Lobo M, Teh BS, Okcu MF, South M, Butler EB, Su J, Chintagumpala M. Ototoxicity After Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy in Children with Medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Mar 13.

Ildefonso CJ, Kong L, Leen A, Chai SJ, Petrochelli V, Chintagumpala M, Hurwitz MY, Chévez-Barrios P, Hurwitz RL. Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma. Mol Ther. 18(10):1885-90 (2010).

Yu L, Baxter PA, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, Man TK, Shu Q, Zhang YJ, Zhao XM, Su JM, Perlaky L, Dauser R, Chintagumpala M, Lau CC, Blaney SM, Rao PH, Leung HC, Li XN. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 12(6):580-94 (2010).

Takei H, Nguyen Y, Mehta V, Chintagumpala M, Dauser RC, Adesina AM. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.J Neurosurg Pediatr. 3(1):61-5 (2009).


Texas Children's Cancer Center Profile